Cart (0)
Your shopping cart is empty!
Dear Customers,
The delivery situation has returned to normal. International shipping services work as usual. We ship all orders placed.
Lavomax (Tiloron) 0,125 N3
Lavomax (Tiloron) 0,125 N3
Product Code: 208192

Lavomax (Tiloron) 0,125 N3

Compare this Product
$12.00
10

The composition and form of issue:

Tablets, film-coated 1 tablet contains:

tiloron 0.125 g

auxiliary substances: to obtain the tablet weight of 0.39 g of magnesium hydroxycarbonate hydrate (magnesium carbonate basic aqueous) povidone (PVP low molecular weight medical, kollidon) calcium stearate silicon dioxide colloidal (Aerosil) beeswax mineral oil sucrose talc tropeolin 0 titanium dioxide polyethylene glycol of high molecular weight 6000 

in a contour acheikova packing 6 or 10 PCs in a pack a cardboard 1 or 2 packs.

Description pharmaceutical form:

Tablets, film-coated from yellow to orange, round shape. In the cross-section are seen 2 layers. - Tablet — orange.

Pharmacological action:

Stimulates the body &alpha-, &beta-, &gamma-interferons. The main producers of interferon in response to the introduction of Lavomax are the cells of the intestinal epithelium, hepatocytes, T-lymphocytes and neutrophils. After intake of maximum production of interferon is defined in the sequence intestine-liver-blood through 4-24 h. Lavomax ® has immunomodulating and antiviral effect.

Stimulates stem cells of bone marrow, depending on the dose increases antibody production, reduces the degree of immunosuppression, restores the ratio of T-helper/T - suppressor. Effective against various viral infections, including against influenza, other acute respiratory viral infections, hepatitis viruses, herpes viruses. The mechanism of antiviral action is associated with inhibition of translation of virus-specific proteins in infected cells, resulting in suppressed reproduction of viruses.

Pharmacokinetics:

After intake of rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. The plasma protein binding is about 80%.

No biotransformation and accumulation in the body.

Excreted almost unchanged in the faeces (70%) and urine (9%). T1/2 is 48 h.

Indications:

  • viral hepatitis A, B, C
  • herpes infection CMV infection
  • infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, avioanele, etc.), urogenital and respiratory chlamydia, negonokokkovi urethritis, tuberculosis (complex therapy)
  • influenza and other ARVI in adults (treatment and prevention).

Contraindications:

  • hypersensitivity to the drug
  • pregnancy and lactation
  • children up to age 18 years.

Side effects:

Allergic reactions, diarrhoeal phenomenon, intermittent fever.

Drug interactions:

Compatible with antibiotics and traditional means of treatment of viral and bacterial diseases. Clinically meaningful interaction Lavomax with these drugs have not been identified.

Method of application and dose:

Inside, after eating.

For non-specific prevention of viral hepatitis A — 0.125 g per week for 6 weeks.

For the treatment of viral hepatitis And 0.125 g 2 times on the first day, and then on the 0,125 grams a day. Heading dose — 1.25 g (10 table.).

For the treatment of acute hepatitis b: first and second days to 0,125 grams and then on the 0,125 grams a day dose is 2 g (16 table). When protracted course of hepatitis b 0.125 g 2 times a day for the first day, and then on the 0,125 grams a day. The course dose of 2.5 g (20 table.)

In chronic hepatitis b in the initial phase of treatment (2.5 g — 20 table.): in the first 2 days — 0.25 g, 0.125 g a day. The continuation phase from 1.25 g (10 table.) to 2.5 g (20 table.) — 0.125 g per week. Heading dose of Lavomax to 3.75–5 g (30 to 40 tab. 0.125 g), the duration of treatment is 3.5–6 months depending on the results of biochemical, immunological and morphological studies, reflecting the degree of activity of the process.

In acute hepatitis C: in the first and second days to 0,125 grams and then on the 0,125 grams a day. The course dose of 2.5 g (20 table.)

In chronic hepatitis C, in the initial phase of treatment (2.5 g — 20 table.): in the first two days — 0.25 g, 0.125 g a day. The continuation phase (2.5 g — 20 table). — 0.125 g per week. Heading dose of Lavomax — 5 g (40 tab. 0.125 g), the duration of therapy — 6 months depending on the results of biochemical, immunological, morphological markers of activity of the process.

In the treatment of influenza and other ARVI in the first two days of illness — 0,125 grams and then on the 0,125 grams a day. Heading dose is 0.75 g (6 table. 0.125 g).

For the prevention of influenza and other acute respiratory viral infections: 0,125 1 g once a week for 6 weeks. On the course — 6 table. 0.125 g.

For the treatment of herpes and CMV infection in the first two days to 0,125 grams and then on the 0,125 grams a day. The course dose of 2.5 g (20 table. 0.125 g).

At the urogenital and respiratory chlamydia: the first two days to 0,125 grams and then on the 0,125 grams a day. Heading dose — 1.25 g (10 table. 0.125 g).

In complex therapy neyrovirushnykh infections: a dose set individually, of treatment is 4 weeks.

In the complex treatment of pulmonary tuberculosis: first two days at 0.25 g then on the 0,125 grams a day. The course dose of 2.5 g (20 table. 0.125 g).

Overdose:

Cases overdose unknown.